Fig. 7: PIM inhibitor pre-treatment increases vascular leakage and tumor cell colonization.

a–d PIM inhibitor AZD-1208 (30 mg kg⁻¹) or vehicle (Ctrl) was orally administered daily for 5 days. On day 3, B16-F10 melanoma cells were injected intravenously (i.v.) and 70 kDa fluorescent dextran was injected for the last 10 min on day 8 (a). Shown are representative confocal images (b, c) and number of metastatic nodules and dextran area quantified from lung sections (d). n = 6 mice per group. e–g AZD-1208 or vehicle (Ctrl) were administered orally daily for 5 days. On day 5, 4T1 cells were i.v. injected into BALB/c female mice (e). Representative images (f) and quantification of metastases from hematoxylin & eosin (H&E) stained lung sections from AZD-1208 and vehicle treated mouse lungs on d 12 (g). n = 4 Ctrl mice; n = 6 mice in AZD-1208 group (f, g) h–j AZD-1208 was administered daily for 4 days prior to LLC i.v. injection into C57BL/6 male mice (h). Shown are representative images of HE stained lung sections (i) and quantification of metastases from AZD-1208 and vehicle (Ctrl) treated mice on d 18. n = 5 mice per group. (j) In each experiment metastases from at least four lung lobes per mouse were analyzed. Scale bar 500 μm (b, f, i), 25 µm (c). Two-tailed unpaired t-test (d, g, j). Data are presented as mean values ⁺/- SD. Illustration created in Biorender.com (a, e, h). Source data are provided as a Source Data file.